Pfizer announced that its vaccine candidate for respiratory syncytial virus is more than 85% effective in preventing lower respiratory tract illness in older adults.
Pfizer's logo is reflected in a drop on a syringe needle in this illustration taken Nov. 9, 2020.Pfizer announced Thursday that its vaccine candidate for respiratory syncytial virus was more than 85% effective in preventing lower respiratory tract illness in older adults.
"We are delighted that this first bivalent RSV vaccine candidate, RSVpreF, was demonstrated to be efficacious in our clinical trial against this disease, which is associated with high levels of morbidity and mortality in older adults," Dr. Annaliesa Anderson, senior vice president and chief scientific officer for vaccine research and development at Pfizer, said in a statement Thursday.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Scientists question Moderna invention claim in COVID-19 vaccine disputeThe makers of the two most widely used COVID19 vaccines in the United States are now in a patent fight over their shots.
Lire la suite »
Moderna sues Pfizer over patents behind COVID-19 vaccineCOVID\u002D19 vaccine maker Moderna is suing Pfizer and German drugmaker BioNTech, accusing its main competitors of copying Moderna\u0027s technology.
Lire la suite »
Moderna patent fight about feathers, not gooseModerna’s claim that the Covid-19 vaccine developed by Pfizer and partner BioNTech used its intellectual property sounds explosive. The sums at stake are potentially huge, as the drug giant estimates sales of the vaccine will be $32 billion this year. It’s in nobody’s interest to kill this golden goose though. The most likely result will simply be lots of legal hissing, and at worst for Pfizer, a few plucked feathers.
Lire la suite »
Black Men Less Likely to Get Monkeypox VaccineNew CDC data shows only 10% of the monkeypox vaccine, Jynneos, have been given to Black people, even though they make up a third of U.S. cases.
Lire la suite »